Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3987-3993

  Gorin, Norbert Claude ^a   Labopin, Myriam ^a   Blaise, Didier ^a   Reiffers, Josy ^a   Meloni, Giovanna ^a   Michallet, Mauricette ^a   De Witte, Theo ^a   Attal, Michel ^a   Rio, Bernard ^a   Witz, Francois ^a   Fouillard, Loic ^a   Willemze, Roel ^a   Rocha, Vanderson ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DISEASE REGISTRY; FEMALE; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 69849107713     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1400     Document Type: Article

References (37)

1. Burnett AK, Goldstone AH, Stevens RMF, et al: Randomised comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC-AML 10 trial. Lancet 351:700-708, 1998
2. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
3. Gorin NC: Autologous stem cell transplantation in acute myelocytic leukemia. Blood 92:1073-1090, 1998
4. Gorin NC: Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol 14:152-159, 2002
5. Harousseau JL, Cahn JY, Pignon B, et al: Comparison of autologous bone marrow transplantation and intensive chemotherapy as post remission therapy in adult acute myeloid leukemia. Blood 90:2978-2986, 1997
6. Linker C: The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Pract Res Clin Haematol 20:77-84, 2007
7. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organisation for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217-223, 1995
8. Gratwohl A, Passweg J, Baldomero H, et al: Blood and marrow transplantation activity in Europe 1997: European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 24:231-245, 1999
9. Gratwohl A, Baldomero H, Schmid O, et al: Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: A report of the EBMT activity survey 2003. Bone Marrow Transplant 36:575-590, 2005
10. Gratwohl A, Baldomero H, Frauendorfer K, et al: The EBMT activity survey 2006 on hematopoietic stem cell transplantation: Focus on the use of cord blood products. Bone Marrow Transplant 41:687-705, 2008
11. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
12. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
13. Fine JP, Gray RG: A proportional hazards model for subdistribution of a competing risk. Jour Am Stat Assoc 94:496-509, 1999
14. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
15. Byar DP: Identification of prognostic factors, in: Buyse ME (ed): Cancer Clinical Trials Methods and Practice. Oxford Medical Publications 423-443, 1988
16. Andersen PK, Klein JP, Zhang MJ: Testing for centre effects in multi-centre survival studies: A Monte Carlo comparison of fixed and random effects tests. Stat Med 18:1489-1500, 1999
17. Hoogard P: Frailty model for survival data. Lifetime Data Anal 1:255-273, 1995
18. Gorin NC, Najman A, Duhamel G: Autologous bone-marrow transplantation in acute myelocytic leukaemia. Lancet 1:1050, 1977
19. Gorin NC: Stem cell in vitro purging for autologous transplantation, in Armitage JO, Antman KH (eds): High Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells. Philadelphia, PA, Lippincott Williams and Wilkins, 2008, pp 355-391
20. Gorin NC, Aegerter P, Auvert B, et al: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606-1614, 1990
21. Gorin NC, Labopin M, Meloni G, et al: Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: Further evidence of the role of marrow purging by mafosfamide: European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 5:896-904, 1991
22. Miller CB, Rowlings PA, Zhang MJ, et al: The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 29:1336-1346, 2001
23. Brenner MK, Rill DR, Moen RC, et al: Genemarking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85-86, 1993
24. Gorin NC, Labopin M, Laporte JP, et al: Importance of marrow dose on posttransplant outcome in acute leukemia: Models derived from patients autografted with mafosfamide-purged marrow at a single institution. Exp Hematol 27:1822-1830, 1999
25. Laporte JP, Douay L, Lopez M, et al: One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: A 10-year single institution experience. Blood 84:3810-3818, 1994
26. Reiffers J, Bernard P, David B, et al: Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 14:312-315, 1986
27. To LB, Haylock DN, Kimber RJ, Juttner CA: High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58:399-410, 1984
28. Laporte JP, Gorin NC, Feuchtenbaum J, et al: Relapse after autografting with peripheral blood stem cells. Lancet 2:1393, 1987
29. Mehta J, Powles R, Singhal S, et al: Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 15:652-653, 1995
30. Sanz MA, De La RJ, Sanz GF, et al: Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: A report from a single institution. J Clin Oncol 11:1661-1667, 1993
31. Feller N, Schuurhuis GJ, van der Pol MA, et al: High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 17:68-75, 2003
32. Melillo L, Cascavilla N, Lerma E, et al: The significance of minimal residual disease in stem cell grafts and the role of purging: Is it better to purge in vivo or in vitro? Acta Haematol 114:206-213, 2005 33. Powles R, Mehta J, Kulkarni S, et al: Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 355:1231-1237, 2000
33. Schmitz N, Beksac M, Bacigalupo A, et al: Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 90:643-648, 2005
34. Reiffers J, Labopin M, Sanz M, et al: Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: An EBMT retrospective analysis. Bone Marrow Transplant 25: 1115-1119, 2000
35. Gorin NC, Labopin M, Frassoni F, et al: Identical outcome following autologous or allogeneic genoidentical hematopoietic stem cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 (inv 16) or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 26:3183-3188, 2008
36. Gorin NC, Labopin M, Pichard P, et al: Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: Importance of the source of stem cells. Br J Haematol 110:887-893, 2000
37. Jourdan E, Rigal-Huguet F, Marit G, et al: One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. Br J Haematol 129:403-410, 2005